Quoin Pharmaceuticals, LTD Form 4 insider transactions

Stonepine Capital Management, LLC has ceased to be a 10% beneficial owner of Quoin Pharmaceuticals, Ltd. due to an increase in outstanding shares.

Quoin Pharmaceuticals' Chief Financial Officer, Sally Bridget Lawlor, was granted 85,250 share options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals Director Joseph Cooper received 8,141 stock options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals Director Anthony James Culverwell was granted 21,709 stock options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals CEO Michael Myers was granted 318,750 share options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals' Chief Operating Officer, Denise Carter, was granted 318,750 stock options with an exercise price of $7.37 per American Depositary Share.

Quoin Pharmaceuticals Director Dennis Langer was granted 21,709 American Depositary Share options with an exercise price of $7.37, vesting over four years.

Quoin Pharmaceuticals director Michael T. Sember was granted 8,141 stock options with an exercise price of $7.37 per American Depositary Share.

Quoin Pharmaceuticals director Natalie Leong received 12,211 stock options with a $7.37 exercise price, vesting over four years.

Quoin Pharmaceuticals' Chief Financial Officer, Sally Bridget Lawlor, was granted 10,330 American Depositary Share options with an exercise price of $19.36.

Quoin Pharmaceuticals Director Dennis Langer acquired 15,152 ADSs and an equal number of Series H, I, J, and K warrants in a private placement.

Quoin Pharmaceuticals' Director, Natalie Ee Mun Leong, was granted 4,105 American Depositary Share options with an exercise price of $9.07, approved by shareholders on August 21, 2025.

Quoin Pharmaceuticals Director Anthony James Culverwell was granted 13,682 stock options at an exercise price of $9.07 per ADS, approved by shareholders on August 21, 2025.

Quoin Pharmaceuticals, Ltd. has granted Director Dennis Langer 13,682 share options at an exercise price of $9.07 per ADS, following shareholder approval.

Quoin Pharmaceuticals, Ltd. filed an amended Form 4 to correct an inadvertent understatement in the number of American Depositary Shares underlying a stock option granted to Chief Operating Officer Denise P. Carter.

Quoin Pharmaceuticals, Ltd. CEO Michael Myers filed an amended Form 4 to correct an inadvertent understatement of American Depositary Shares (ADSs) underlying a stock option granted on May 29, 2025.

Quoin Pharmaceuticals Director Anthony James Culverwell was granted 7,760 American Depositary Share options with an exercise price of $9.07, vesting over four years.

Quoin Pharmaceuticals CEO Michael Myers was granted 42,039 American Depositary Share options with an exercise price of $9.07, vesting over four years.

Denise P. Carter, Chief Operating Officer and Director of Quoin Pharmaceuticals, Ltd., was granted 42,039 stock options at an exercise price of $9.07 per American Depositary Share (ADS) on May 29, 2025.

Quoin Pharmaceuticals Director Natalie Leong was granted 7,760 share options with an exercise price of $9.07 per American Depositary Share, vesting over four years.

Quoin Pharmaceuticals, Ltd. Director Dennis Langer was granted 7,760 American Depositary Share (ADS) options with an exercise price of $9.07, vesting over four years.

Joseph Patrick Cooper, a Director at Quoin Pharmaceuticals, Ltd., was granted 7,760 share options with an exercise price of $9.07 per American Depositary Share (ADS), vesting over four years.

Quoin Pharmaceuticals, Ltd. Director Michael T. Sember was granted options to purchase 7,760 American Depositary Shares (ADSs) at an exercise price of $9.07 per ADS, as disclosed in a recent SEC Form 4 filing.

Denise P. Carter, COO of Quoin Pharmaceuticals, acquired shares and warrants through a public offering on December 23, 2024.

CEO Michael Myers reports acquisition of Quoin Pharmaceuticals shares and warrants at $0.45 per unit in a recent public offering.

Gordon Dunn, CFO of Quoin Pharmaceuticals, acquired shares and warrants in the company's recent public offering at a price of $0.45 per unit.

Director Anthony James Culverwell purchased 100,000 ordinary shares and warrants in Quoin Pharmaceuticals' public offering at $0.45 per share.

Quoin Pharmaceuticals has granted share options to Joseph Patrick Cooper, vesting over four years, with the exercise price at $0.78 per American Depositary Share.

Quoin Pharmaceuticals' Chief Financial Officer, Gordon Dunn, has been granted share options that vest over four years.

Quoin Pharmaceuticals has granted share options to Anthony James Culverwell, vesting over four years.